Health
Orchard Therapeutics Announces Last Patient Treated in Registrational Trial of OTL-203 for MPS-I Hurler Syndrome
Completion of enrollment achieved nearly one year ahead of schedule Primary analysis anticipated two years post-treatment TOKYO and LONDON and BOSTON, July 07, 2025 (GLOBE NEWSWIRE) -- Orchard Therapeutics, a Kyowa Kirin company, today announced the last patient has been treated in a registrational trial evaluating the efficacy and safety of OTL-203, an investigational hematopoietic stem cell (HSC) gene therapy, in patients with the Hurler subtype of mucopolysaccharidosis type I (MPS-IH). The tr
About this update from Kyowa Kirin Co., Ltd.
[{"type":"image","alt":"Orchard Therapeutics (Europe) Limited","displaySize":"","headline":null,"caption":"Orchard Therapeutics (Europe) Limited","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":149,"url":"https://media.zenfs.com/en/globenewswire.com/f7c5ab86662cc16a57f6f696e0294e9f"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/835KIgttjwaVXyE.TnVDAg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTIwOTtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/f7c5ab86662cc16a57f6f696e0294e9f","width":300,"height":149}},"lazy":false},{"type":"text","content":"Completion of enrollment achieved nearly one year ahead of schedule","length":67,"tagName":"p"},{"type":"text","content":"Primary analysis anticipated two years post-treatment","length":53,"tagName":"p"},{"type":"text","content":"TOKYO and LONDON and BOSTON, July 07, 2025 (GLOBE NEWSWIRE) -- Orchard Therapeutics, a Kyowa Kirin company, today announced the last patient has been treated in a registrational trial evaluating the efficacy and safety of OTL-203, an investigational hematopoietic stem cell (HSC) gene therapy, in patients with the Hurler subtype of mucopolysaccharidosis type I (MPS-IH). The trial (NCT06149403), referred to as HURCULES, compares treatment with OTL-203 to standard of care with allogeneic hematopoietic stem cell transplant (allo-HSCT).","length":537,"tagName":"p"},{"type":"text","content":"MPS-I is a rare, inherited neurometabolic disease caused by a deficiency of the alpha-L-iduronidase (IDUA) lysosomal enzyme resulting in the accumulation of glycosaminoglycans (GAGs) in multiple organs, including the musculoskeletal and central nervous systems, as well as the heart, eyes, and ears. It is estimated to occur globally in 1 in 100,000 live births. Approximately 60 percent of children born with MPS-I have the most severe subtype, MPS-IH, also called Hurler syndrome, and rarely live past the age of 10 when untreated. Current treatment options for MPS-IH include allo-HSCT and enzyme replacement therapy (ERT), both of which have significant limitations.","length":670,"tagName":"p"},{"type":"text","content":"“The completion of study enrollment nearly a year ahead of schedule underscores the urgent medical need that still exists in MPS-IH, and the hopefulness of physicians and patients to contribute to the development of new treatment options,” said Leslie Mel...